^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Malignant Pleural Mesothelioma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    Recommendations...Systemic therapy for second line and beyond…Single-agent nivolumab is superior to BSC in pretreated immunotherapy-naive patients and is a treatment option [I, A].
    DOI:
    https://doi.org/10.1016/j.annonc.2021.11.005
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...the NCCN panel recommends the following subsequent immunotherapy options for patients with MPM:…2) nivolumab with (or without) ipilimumab…